Suyu Liu

List of Publications by Year
in descending order

26	1,538	623734	713466
papers	**citations**	14	21
		h-index	**g-index**

26	26	26	1889
all docs	**docs citations**	**times ranked**	**citing authors**

#	Article	IF	Citations
1	The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery, 2011, 1, 44-53.	9.4	778
2	Bayesian adaptive design for targeted therapy development in lung cancer â€" a step toward personalized medicine. Clinical Trials, 2008, 5, 181-193.	1.6	199
3	Bayesian adaptive randomization designs for targeted agent development. Clinical Trials, 2010, 7, 584-596.	1.6	95
4	Using Data Augmentation to Facilitate Conduct of Phase Iâ€"II Clinical Trials With Delayed Outcomes. Journal of the American Statistical Association, 2014, 109, 525-536.	3.1	86
5	Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Annals of Applied Statistics, 2013, 7, 1837-2457.	1.1	58
6	A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	51
7	A robust Bayesian dose-finding design for phase I/II clinical trials. Biostatistics, 2016, 17, 249-263.	1.5	49
8	A Bayesian Phase I/II Trial Design for Immunotherapy. Journal of the American Statistical Association, 2018, 113, 1016-1027.	3.1	38
9	Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discovery, 2021, 11, 2738-2747.	9.4	37
10	A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine, 2014, 33, 4017-4028.	1.6	26
11	Up-and-down designs for phase I clinical trials. Contemporary Clinical Trials, 2013, 36, 218-227.	1.8	24
12	A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Bayesian Analysis, 2013, 8, 703-722.	3.0	22
13	Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences, 2016, 8, 99-128.	1.2	22
14	Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. Cancer Prevention Research, 2021, 14, 729-740.	1.5	16
15	A Utility-Based Bayesian Phase Iâ€"II Design for Immunotherapy Trials with Progression-Free Survival End Point. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 411-425.	1.0	13
16	Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics, 2022, 78, 60-71.	1.4	8
17	An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints. Biometrical Journal, 2020, 62, 339-349.	1.0	7
18	A Bayesian Phase I/II Design for Cancer Clinical Trials Combining an Immunotherapeutic Agent with a Chemotherapeutic Agent. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 1210-1229.	1.0	3

#	Article	IF	Citations
19	Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. Clinical Lung Cancer, 2022, 23, 185-190.	2.6	3
20	On the coherence of model-based dose-finding designs for drug combination trials. PLoS ONE, 2020, 15, e0242561.	2.5	2
21	A randomized group sequential enrichment design for immunotherapy and targeted therapy. Contemporary Clinical Trials, 2022, , 106742.	1.8	1
22	Hybrid design evaluating new biomarkers when there is an existing screening test. Statistics in Medicine, 2021, 40, 2037-2054.	1.6	0
23	On the coherence of model-based dose-finding designs for drug combination trials. , 2020, 15, e0242561.		0
24	On the coherence of model-based dose-finding designs for drug combination trials. , 2020, 15, e0242561.		0
25	On the coherence of model-based dose-finding designs for drug combination trials. , 2020, 15, e0242561.		0
26	On the coherence of model-based dose-finding designs for drug combination trials. , 2020, 15, e0242561.		0